



## **UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023**

November 7, 2023

*Conference Call and Webcast Scheduled for Tuesday, November 14, 2023 at 10:00 AM ET*

PRINCETON, N.J.--(BUSINESS WIRE)--Nov. 7, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2023 financial results on November 14, 2023, at 8:00 AM EDT, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen's [Investor Relations website](#). Following the live webcast, a replay will be available on the site for approximately 30 days.

### **About UroGen Pharma Ltd.**

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. JELMYTO® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit [www.urogen.com](http://www.urogen.com) to learn more or follow us on Twitter, @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231107012900/en/): <https://www.businesswire.com/news/home/20231107012900/en/>

### **INVESTOR CONTACT:**

Vincent Perrone  
[vincent.perrone@urogen.com](mailto:vincent.perrone@urogen.com)  
(609) 460-3588

### **MEDIA CONTACT:**

Cindy Romano  
[Cindy.romano@urogen.com](mailto:Cindy.romano@urogen.com)  
(609) 460-3583

Source: UroGen Pharma Ltd.